Author

V. Wiebking

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Chandra· 1 shared A. E. Baxter· 1 shared A. J. Dimitri· 1 shared B. L. Levine· 1 shared B. T. Dejene· 1 shared C. H. Holliday· 1 shared C. Lee· 1 shared C. Nicolas· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Chandra

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function

A. J. Dimitri, A. E. Baxter, G. M. Chen, C. R. Hopkins, G. T. Rouin, H. Huang, W. Kong, C. H. Holliday, V. Wiebking, R. Bartoszek, S. Drury, K. Dalton, O. M. Koucky, Z. Chen, J. R. Giles, , J. A. Fraietta

This study shows that targeting TET2 in CAR T-cells improves their anti-tumor responses by limiting terminal exhaustion and enhancing therapeutic potential.

bioRxiv · Mar 29, 2024Immunology

Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells

M. Pavel-Dinu, V. Wiebking, B. T. Dejene, W. Srifa, S. Mantri, C. Nicolas, C. Lee, G. Bao, E. J. Kildebeck, N. Punjya, C. Sindhu, M. A. Inlay, N. Saxena, S. S. DeRavin, H. Malech, , M. Porteus

This study corrects SCID-X1 in hematopoietic stem cells using CRISPR/Cas9, achieving high integration frequencies and low off-target effects, supporting clinical development.

bioRxiv · Aug 22, 2018Bioengineering